FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2917228511> ?p ?o ?g. }

• W2917228511 endingPage "187" @default.
• W2917228511 startingPage "182" @default.
• W2917228511 abstract "Haploidentical stem cell transplantation (haplo SCT) has emerged as an acceptable alternative to matched family donor transplantation for children diagnosed to have primary immune deficiency disorders (PIDs). We present data over 4 years on the challenges and efficacy of unmanipulated T cell replete haplo SCTs with post-transplant cyclophosphamide (PTCy) in children diagnosed to have PIDs. We performed a retrospective study in the pediatric blood and marrow transplantation unit where all children less than 18 years of age diagnosed to have PIDs and who underwent haplo SCT with PTCy from January 2014 to February 2018 were included in the study. Of the 16 transplants included in the study, 5 children were diagnosed to have Wiskott-Aldrich syndrome, 3 with congenital hemophagocytic lymphohistiocytosis, 2 each with Griscelli syndrome and Mendelian susceptibility to mycobacterial diseases, and one each with Chediak-Higashi syndrome, ORAI 1 mutation immune deficiency, severe combined immune deficiency, and Hyper IgM syndrome. The source of stem cells was PBSC in 62.5% and bone marrow in 32.5%. Engraftment by day 16–21 post hematopoietic stem cell transplantation was achieved in 75% transplants with 91% of these remaining in sustained complete chimerism. Acute skin and gut graft versus host disease of grade 2–3 were noted in 50% transplants and cytomegalovirus (CMV) reactivation in 43.7% transplants. One child with congenital HLH succumbed to refractory CMV, adenovirus, and BK virus infection. Cytokine release syndrome (CRS) was noted in 75% transplants with 2 children succumbing to the illness. Tocilizumab was successfully used early in one child. Overall mortality was found to be 37.5% with overall survival of 62.5% with a median follow-up of 23.3 months. In resource limited settings, PTCy has the potential to provide a cost-effective advantage in terms of accessibility of this curative procedure among children with PIDs." @default.
• W2917228511 created "2019-03-02" @default.
• W2917228511 creator A5010821168 @default.
• W2917228511 creator A5017204598 @default.
• W2917228511 creator A5030029087 @default.
• W2917228511 creator A5038920089 @default.
• W2917228511 creator A5048583711 @default.
• W2917228511 creator A5056304701 @default.
• W2917228511 creator A5063242157 @default.
• W2917228511 creator A5064378477 @default.
• W2917228511 creator A5084220970 @default.
• W2917228511 creator A5086414382 @default.
• W2917228511 date "2019-02-01" @default.
• W2917228511 modified "2023-10-03" @default.
• W2917228511 title "Haploidentical Stem Cell Transplantation with Post-Transplant Cyclophosphamide for Primary Immune Deficiency Disorders in Children: Challenges and Outcome from a Tertiary Care Center in South India" @default.
• W2917228511 cites W1545823153 @default.
• W2917228511 cites W1818576030 @default.
• W2917228511 cites W2041380049 @default.
• W2917228511 cites W2056037925 @default.
• W2917228511 cites W2066886754 @default.
• W2917228511 cites W2117403402 @default.
• W2917228511 cites W2134678353 @default.
• W2917228511 cites W2289914793 @default.
• W2917228511 cites W2423750562 @default.
• W2917228511 cites W2515839675 @default.
• W2917228511 cites W2624933871 @default.
• W2917228511 cites W2743113491 @default.
• W2917228511 cites W2754125581 @default.
• W2917228511 cites W2800384533 @default.
• W2917228511 cites W2888262972 @default.
• W2917228511 doi "https://doi.org/10.1007/s10875-019-00600-z" @default.
• W2917228511 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7100782" @default.
• W2917228511 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30778805" @default.
• W2917228511 hasPublicationYear "2019" @default.
• W2917228511 type Work @default.
• W2917228511 sameAs 2917228511 @default.
• W2917228511 citedByCount "37" @default.
• W2917228511 countsByYear W29172285112019 @default.
• W2917228511 countsByYear W29172285112020 @default.
• W2917228511 countsByYear W29172285112021 @default.
• W2917228511 countsByYear W29172285112022 @default.
• W2917228511 countsByYear W29172285112023 @default.
• W2917228511 crossrefType "journal-article" @default.
• W2917228511 hasAuthorship W2917228511A5010821168 @default.
• W2917228511 hasAuthorship W2917228511A5017204598 @default.
• W2917228511 hasAuthorship W2917228511A5030029087 @default.
• W2917228511 hasAuthorship W2917228511A5038920089 @default.
• W2917228511 hasAuthorship W2917228511A5048583711 @default.
• W2917228511 hasAuthorship W2917228511A5056304701 @default.
• W2917228511 hasAuthorship W2917228511A5063242157 @default.
• W2917228511 hasAuthorship W2917228511A5064378477 @default.
• W2917228511 hasAuthorship W2917228511A5084220970 @default.
• W2917228511 hasAuthorship W2917228511A5086414382 @default.
• W2917228511 hasBestOaLocation W29172285111 @default.
• W2917228511 hasConcept C104317684 @default.
• W2917228511 hasConcept C126322002 @default.
• W2917228511 hasConcept C159654299 @default.
• W2917228511 hasConcept C187212893 @default.
• W2917228511 hasConcept C203014093 @default.
• W2917228511 hasConcept C2776694085 @default.
• W2917228511 hasConcept C2776755627 @default.
• W2917228511 hasConcept C2777385706 @default.
• W2917228511 hasConcept C2777408962 @default.
• W2917228511 hasConcept C2778153459 @default.
• W2917228511 hasConcept C2779019163 @default.
• W2917228511 hasConcept C2779079688 @default.
• W2917228511 hasConcept C2779134260 @default.
• W2917228511 hasConcept C2779972918 @default.
• W2917228511 hasConcept C2780194698 @default.
• W2917228511 hasConcept C2781128166 @default.
• W2917228511 hasConcept C28328180 @default.
• W2917228511 hasConcept C2911091166 @default.
• W2917228511 hasConcept C54355233 @default.
• W2917228511 hasConcept C55493867 @default.
• W2917228511 hasConcept C71924100 @default.
• W2917228511 hasConcept C86803240 @default.
• W2917228511 hasConcept C8891405 @default.
• W2917228511 hasConceptScore W2917228511C104317684 @default.
• W2917228511 hasConceptScore W2917228511C126322002 @default.
• W2917228511 hasConceptScore W2917228511C159654299 @default.
• W2917228511 hasConceptScore W2917228511C187212893 @default.
• W2917228511 hasConceptScore W2917228511C203014093 @default.
• W2917228511 hasConceptScore W2917228511C2776694085 @default.
• W2917228511 hasConceptScore W2917228511C2776755627 @default.
• W2917228511 hasConceptScore W2917228511C2777385706 @default.
• W2917228511 hasConceptScore W2917228511C2777408962 @default.
• W2917228511 hasConceptScore W2917228511C2778153459 @default.
• W2917228511 hasConceptScore W2917228511C2779019163 @default.
• W2917228511 hasConceptScore W2917228511C2779079688 @default.
• W2917228511 hasConceptScore W2917228511C2779134260 @default.
• W2917228511 hasConceptScore W2917228511C2779972918 @default.
• W2917228511 hasConceptScore W2917228511C2780194698 @default.
• W2917228511 hasConceptScore W2917228511C2781128166 @default.
• W2917228511 hasConceptScore W2917228511C28328180 @default.
• W2917228511 hasConceptScore W2917228511C2911091166 @default.
• W2917228511 hasConceptScore W2917228511C54355233 @default.
• W2917228511 hasConceptScore W2917228511C55493867 @default.
• W2917228511 hasConceptScore W2917228511C71924100 @default.

• next